DXC-008

N/A

Report date: 2025/02/26 17:19:08

Base Information

Drug NameDXC-008
Drug Alias NameDAC-008DXC-008
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionSix-transmembrane epithelial antigen of the prostate 1modulatorsProstate-Specific Membrane Antigen modulators
TargetsSix-transmembrane epithelial antigen of the prostate 1Prostate-Specific Membrane Antigen
Therapy Area/IndicationsSolid tumoursProstatic NeoplasmsSarcoma, Ewing
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesHangzhou Dac Biotech Company Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesHangzhou Dac Biotech Company Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursProstatic NeoplasmsSarcoma, Ewing
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A